[177Lu]Bz-DTPA-EGF: Preclinical characterization of a potential radionuclide targeting agent against glioma

Cancer Biotherapy and Radiopharmaceuticals

Volumn 19, Issue 2, 2004, Pages 195-204

  Sundberg, Åsa Liljegren ^a,b   Gedda, Lars ^a   Orlova, Anna ^a   Bruskin, Alexander ^a   Blomquist, Erik ^a   Carlsson, Jörgen ^a   Tolmachev, Vladimir ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Biodistribution; Bz DTPA; Cellular processing; EGF; Glioma; Lutetium 177; Radionuclide therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR BENZYLPENTETATE IN 111; EPIDERMAL GROWTH FACTOR BENZYLPENTETATE LU 177; EPIDERMAL GROWTH FACTOR RECEPTOR; LIGAND; LUTETIUM; LUTETIUM 177; PENTETATE INDIUM IN 111; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; CHELATING AGENT; PENTETIC ACID; RADIOISOTOPE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG TARGETING; DRUG UPTAKE; FEMALE; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; ISOTOPE LABELING; KIDNEY; LIGAND BINDING; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOISOTOPE DISTRIBUTION; ANIMAL; ARTICLE; CHEMISTRY; DRUG SCREENING; MOUSE STRAIN; PROTEIN BINDING; SENSITIVITY AND SPECIFICITY; SYNTHESIS; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CHELATING AGENTS; DRUG EVALUATION, PRECLINICAL; EPIDERMAL GROWTH FACTOR; GLIOBLASTOMA; HUMANS; LUTETIUM; MICE; MICE, INBRED STRAINS; PENTETIC ACID; PROTEIN BINDING; RADIOISOTOPES; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

EID: 2542472217     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497804323071977     Document Type: Conference Paper

References (40)

1. Carlsson J, Forsell Aronsson E, Hietala S-O, et al. Tumor therapy with radionuclides: Assessment of progress and problems. Radiother Oncol 2003;66:107.
2. Cheson BD. Radioimmunotherapy of non-Hodgkin lymphomas. Blood 2003;101:391.
3. Juweid ME. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: From clinical trials to clinical practice. J Nucl Med 2002;43:1507.
4. Paganelli G et al. 90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies. Biopolymers 2002;66:393.
5. Paganelli G et al. Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide. Eur J Nucl Med 2001;28:426.
6. Waldherr C, Pless M, Maecke HR, et al. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumors: A clinical phase II study. Ann Oncol 2001;12:941.
7. Paganelli G et al. Pretargeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: Phase I study and preliminary therapeutic results. Cancer Biother Radiopharm 2001;16:227.
8. Riva P et al. Locoregional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: A phase I study. Clin Canc Res 1999;5:3275S.
9. Hofer S et al. Successful diffusible brachytherapy (dBT) of a progressive low-grade astrocytoma using the locally injected peptide vector and somatostatin analogue [90Y]-DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC). Swiss Med Wkly 2001;131:640.
10. Merlo A et al. Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTA-TOC): A pilot study in human gliomas. Clin Canc Res 1999;5:1025.
11. Schumacher T et al. Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: An extended pilot study. Eur J Nucl Med Mol Imaging 2002;29:486.
12. Barker FG 2 et al. EGFR overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2001;51:410.
13. Huncharek M, Kupelnick B. Epidermal growth factor receptor gene amplification as a prognostic marker in glioblastoma multiforme: Results of a meta-analysis. Oncol Res 2000;12:107.
14. Kleihues P, Ohgaki H. Primary and secondary glioblastomas: From concept to clinical diagnosis. Neuro-oncol 1999;1:44.
15. Watanabe K et al. Overexpression of the EGF-receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996;6:217.
16. Moghal N, Sternberg PW. Multiple positive and negative regulators of signaling by the EGF-receptor. Curr Opin Cell Biol 1999;11:190.
17. DeWitt A et al. Affinity regulates spatial range of EGF-receptor autocrine ligand binding. Dev Biol 2002;250:305.
18. O'Donoghue JA, Bardiès M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 1995;36:1902.
19. Wheldon TE, O'Donoghue JA, Barrett A, et al. The curability of tumors of differing size by targeted radiotherapy using 131I or 90Y. Radiother Oncol 1991;21:91.
20. 177Lu-labeled analogs only. J Nucl Med 2002;43:123P.
21. Sundberg AL et al. [(111)In]Bz-DTPA-hEGF: Preparation and in vitro characterization of a potential anti-glioblastoma targeting agent. Cancer Biother Radiopharm 2003;18:643.
22. Williams M, Rapoport H. Synthesis of enantiomerically pure diethylenetriaminepentaacetic acid analogues. L-phenylalanine as the educt for substitution at the central acetic acid. J Org Chem 1993;58:1151.
23. Westermark B, Magnusson A, Heldin CH. Effect of epidermal growth factor on membrane motility and cell locomotion in cultures of human clonal glioma cells. J Neurosci Res 1982;8:491.
24. Breeman WA et al. Antitumor effect and increased survival after treatment with [177Lu-DOTA0-Tyr3] octreotate in a rat liver micrometastases model. Int J Cancer 2003;104:376.
25. De Jong M et al. [177Lu-DOTA(0)-Tyr3] ocetreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer 2001;92:628.
26. Kwekkeboom DJ et al. Treatment of patients with gastroentero-pancreatic (GEP) tumors with the novel radiolabeled somatostatin analogue [(177)Lu-DOTA(0)-Tyr(3)] octreotate. Eur J Nucl Med Mol Imaging 2003;30:417.
27. De Jong M et al. Preclinical comparison of [DTPA0] octreotide, [DTPA0-Tyr3] octreotide, and [DOTA0-Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Int J Cancer 1998;75:406.
28. De Jong M et al. Yttrium-90 and indium-111 labeling, receptor binding, and biodistribution of [DOTA0-D-Phe1-Tyr3] octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 1997;24:368.
29. Hartman T, Lundqvist H, Westlin JE, et al. Radiation doses to the cell nucleus in single cells and cells in micrometastases in targeted therapy with (131)I-labeled ligands or antibodies. Int J Radiat Oncol Biol Phys 2000;46:1025.
30. Benveniste R, Danoff TM, Ilekis J, et al. Epidermal growth factor receptor numbers in male and female mouse primary hepatocyte cultures. Cell Biochem Funct 1988;6:231.
31. Nagao K et al. Expression of molecular marker genes in various types of normal tissue: Implication for detection of micrometastases. Int J Mol Med 2002;10:307.
32. Wilson JA, Rogers MJ, Hawkins RA, et al. Epidermal growth factor receptors and oestrogen receptors in the head and neck. Clin Otolaryngol 1993;18:66.
33. Yanai S, Sugiyama Y, Iga T, et al. Kinetic analysis of the downregulation of epidermal growth factor receptors in rats in vivo. Am J Physiol 1990;258:C593.
34. Merlo A et al. Biodistribution of 111In-labeled SCN-bz-DTPA-BC-2-MAb following locoregional injection into glioblastomas. Int J Cancer 1997;71:810.
35. Govindan SV et al. Use of galactosylated-streptavidin as a clearing agent with 111In-labeled, biotinylated antibodies to enhance tumor/nontumor localization ratios. Cancer Biother Radiopharm 2002;17:307.
36. Mattes MJ. Biodistribution of antibodies after intraperitoneal or intravenous injection and effect of carbohydrate modifications. J Natl Cancer Inst 1987;79:855.
37. Patel S, Stein R, Ong GL, et al. Enhancement of tumor-to-nontumor localization ratios by hepatocyte-directed blood clearance of antibodies labeled with certain residualizing radiolabels. J Nucl Med 1999;40:1392.
38. Stein R, Goldenberg DM, Ong GL, et al. Manipulation of blood clearance to optimize delivery of residualizing label-antibody conjugates to tumor cells in vivo. J Nucl Med 1997;38:1392.
39. Li WP et al. Development of an in vitro model for assessing the in vivo stability of lanthanide chelates. Nucl Med Biol 2001;28:145.
40. Stimmel JB, Kull FC. Samarium-153 and lutetium-177 chelation properties of selected macrocyclic and acyclic ligands. Nucl Med Biol 1998;25:117.